MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.

Regulation of the MYC oncogene remains unclear. Using 10058-F4, a compound that inhibits MYC-MAX transcription factor, MYC protein and gene expression were down-regulated in Namalwa cells, a Burkitt lymphoma. Compound 10058-F4 decreased MYC mRNA (45%), MYC protein (50%), and cell growth (32%). MYC-MAX transcription factor was disrupted 24 h after treatment, resulting in transcriptional inhibition of target genes. Because microRNAs (miRNA) disrupt mRNA translation, let-7a, let-7b, and mir-98 were selected using bioinformatics for targeting MYC. Inhibition of MYC-MAX transcription factor with 10058-F4 increased levels of members of the let-7 family. In inhibited cells at 24 h, let-7a, let-7b, and mir-98 were induced 4.9-, 1.3-, and 2.4-fold, respectively, whereas mir-17-5p decreased 0.23-fold. These results were duplicated using microRNA multianalyte suspension array technology. Regulation of MYC mRNA by let-7a was confirmed by transfections with pre-let-7a. Overexpression of let-7a (190%) decreased Myc mRNA (70%) and protein (75%). Down-regulation of Myc protein and mRNA using siRNA MYC also elevated let-7a miRNA and decreased Myc gene expression. Inverse coordinate regulation of let-7a and mir-17-5p versus Myc mRNA by 10058-F4, pre-let-7a, or siRNA MYC suggested that both miRNAs are Myc-regulated. This supports previous results in lung and colon cancer where decreased levels of the let-7 family resulted in increased tumorigenicity. Here, pre-let-7a transfections led to down-regulation of expression of MYC and its target genes and antiproliferation in lymphoma cells. These findings with let-7a add to the complexity of MYC regulation and suggest that dysregulation of these miRNAs participates in the genesis and maintenance of the lymphoma phenotype in Burkitt lymphoma cells and other MYC-dysregulated cancers.

[1]  D. Bartel,et al.  MicroRNAs Modulate Hematopoietic Lineage Differentiation , 2004, Science.

[2]  C. Llave,et al.  Cleavage of Scarecrow-like mRNA Targets Directed by a Class of Arabidopsis miRNA , 2002, Science.

[3]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[4]  E. Passegué,et al.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch , 2006, Proceedings of the National Academy of Sciences.

[5]  Yang Yu,et al.  Evidence that microRNAs are associated with translating messenger RNAs in human cells , 2006, Nature Structural &Molecular Biology.

[6]  G. Evan,et al.  The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. , 1993, The EMBO journal.

[7]  Robert B Boxer,et al.  Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. , 2004, Cancer cell.

[8]  A. Grinberg,et al.  Visualization of Myc/Max/Mad Family Dimers and the Competition for Dimerization in Living Cells , 2004, Molecular and Cellular Biology.

[9]  V. Kim,et al.  MicroRNA maturation: stepwise processing and subcellular localization , 2002, The EMBO journal.

[10]  V. Kim,et al.  The Drosha-DGCR8 complex in primary microRNA processing. , 2004, Genes & development.

[11]  B. Vennstrom,et al.  Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29 , 1982, Journal of virology.

[12]  G. Hannon,et al.  Control of translation and mRNA degradation by miRNAs and siRNAs. , 2006, Genes & development.

[13]  Gary Ruvkun,et al.  Identification of many microRNAs that copurify with polyribosomes in mammalian neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[15]  W. Filipowicz,et al.  Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. , 2004, RNA.

[16]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[17]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[18]  D. Felsher,et al.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. , 2003, Blood.

[19]  Anton J. Enright,et al.  Identification of Virus-Encoded MicroRNAs , 2004, Science.

[20]  Adam A. Margolin,et al.  Reverse engineering of regulatory networks in human B cells , 2005, Nature Genetics.

[21]  Xiaobo X. Cao,et al.  Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. , 2002, The Journal of thoracic and cardiovascular surgery.

[22]  J. Sedivy,et al.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[23]  M. A. Valencia Sanchez.  Control of translation and mRNA degradation by miRNAs and siRNAs , 2006 .

[24]  G. Hutvagner,et al.  A microRNA in a Multiple-Turnover RNAi Enzyme Complex , 2002, Science.

[25]  A. Pasquinelli,et al.  Regulation by let-7 and lin-4 miRNAs Results in Target mRNA Degradation , 2005, Cell.

[26]  L. M. Facchini,et al.  The molecular role of Myc in growth and transformation: recent discoveries lead to new insights , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  Y. Akao,et al.  let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. , 2006, Biological & pharmaceutical bulletin.

[28]  R. Eisenman,et al.  Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells , 1984, Molecular and cellular biology.

[29]  Stella Pelengaris,et al.  Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis , 2004, BMC Biology.

[30]  Catherine M Shachaf,et al.  Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. , 2005, Cancer research.

[31]  J. Lawrence,et al.  Sensitive, high-resolution chromatin and chromosome mapping in situ: Presence and orientation of two closely integrated copies of EBV in a lymphoma line , 1988, Cell.

[32]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[33]  Michael T. McManus,et al.  MicroRNAs and cancer. , 2003, Seminars in cancer biology.

[34]  Vincent De Guire,et al.  An E2F/miR-20a Autoregulatory Feedback Loop* , 2007, Journal of Biological Chemistry.

[35]  E. Baehrecke.  miRNAs: Micro Managers of Programmed Cell Death , 2003, Current Biology.

[36]  J. Bishop,et al.  The MYC protein activates transcription of the alpha‐prothymosin gene. , 1991, The EMBO journal.

[37]  Oliver Hobert,et al.  Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions , 2006, Nature Structural &Molecular Biology.

[38]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[39]  C. Dang,et al.  Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc* , 2000, The Journal of Biological Chemistry.

[40]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[41]  Oliver Hobert,et al.  MicroRNAs acting in a double-negative feedback loop to control a neuronal cell fate decision. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Arvanitis,et al.  Conditional transgenic models define how MYC initiates and maintains tumorigenesis. , 2006, Seminars in cancer biology.

[43]  Tatjana Marinkovic,et al.  Reversible lymphomagenesis in conditionally c‐MYC expressing mice , 2004, International journal of cancer.

[44]  R. Eisenman,et al.  New light on Myc and Myb. Part I. Myc. , 1990, Genes & development.

[45]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[46]  Ilsa Gómez-Curet,et al.  c-Myc inhibition negatively impacts lymphoma growth. , 2006, Journal of pediatric surgery.

[47]  M. Cole,et al.  The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation , 1999, Oncogene.

[48]  P. Leder,et al.  Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. , 1984, Science.

[49]  Anwar Hossain,et al.  Mir-17-5p Regulates Breast Cancer Cell Proliferation by Inhibiting Translation of AIB1 mRNA , 2006, Molecular and Cellular Biology.

[50]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[51]  R. Eisenman,et al.  New light on Myc and Myb. Part II. Myb. , 1990, Genes & development.

[52]  J. M. Thomson,et al.  Direct Regulation of an Oncogenic Micro-RNA Cluster by E2F Transcription Factors* , 2007, Journal of Biological Chemistry.